A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
Completed · Phase 1 · NCT07118215
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $8,090
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 62
About the trial
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Tested
- KarXT (drug), Midazolam (drug), Fexofenadine (drug), Digoxin (drug)
- Dates
- Started 2025-09-29; completion 2026-06-25
- Results posted
- Not yet
The purpose of this study is to evaluate the effects of KarXT administration on the drug levels of midazolam, fexofenadine, and digoxin in healthy adult participants.
From ClinicalTrials.gov, last updated 2026-07-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $8,090 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pra Health Sciences- Lenexa $8,090
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.